Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7811645 | 1.00 | CHRNA7 (0.38) | CHRNA7 | |
| SCHEMBL7820147 | 0.87 | CHRNA7 (0.43) | CHRNA7 | |
| Maleic Acid SCHEMBL29496245 | 0.74 | CHRNA7 (0.39) | CHRNA7 | |
| Maleic Acid SCHEMBL9854125 | 0.74 | CHRNA7 (0.39) | CHRNA7 | |
| Maleic Acid SCHEMBL194353 | 0.74 | CHRNA7 (0.39) | CHRNA7 | |
| Fumaric Acid SCHEMBL9342821 | 0.69 | CHRNA7 (0.37) | CHRNA7 | |
| Fumaric Acid SCHEMBL7825260 | 0.69 | CHRM2 (0.53) | — | |
| Fumaric Acid SCHEMBL7825256 | 0.69 | CHRM2 (0.53) | — | |
| Fumaric Acid SCHEMBL7819005 | 0.67 | CHRM1 (0.51) | — | |
| Fumaric Acid SCHEMBL7819001 | 0.67 | CHRM1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6281233-B1 | AZABICYCLIC RING-SUBSTITUTED THIA- OR OXADIAZOLES | NOVO NORDISK A/S (DK) | 2001-08-28 | — | — | US | disclosed |
| US-6281232-B1 | AZABICYCLIC RING-SUBSTITUTED THIA- OR OXADIAZOLES | NOVO NORDISK A/S (DK) | 2001-08-28 | — | — | US | disclosed |
| US-6271229-B1 | ADMINISTERING A 1,2,5-OXADIAZOLE COMPOUND OR 1,2,5-THIADIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 2001-08-07 | — | — | US | disclosed |
| US-6265419-B1 | IRRITABLE BOWEL DISORDER | NOVO NORDISK A/S (DK) | 2001-07-24 | — | — | US | disclosed |
| EP-0714394-B1 | ANTIPSYCHOTIC METHOD WITH THIADIAZOLE AND OXADIAZOLE DERIVATIVES | NOVO NORDISK AS (DK) | 2001-06-20 | — | — | EP | disclosed |
| US-5968926-A | SCHIZOPHRENIA TREATMENT WITH 1,2,5-OXADIAZOLE OR 1,2,5-THIADIAZOLE | NOVO NORDISK A/S (DK) | 1999-10-19 | — | — | US | disclosed |
| US-5663182-A | ADMINISTERING AN AZABICYCLIC RING SUBSTITUTED THIADIAZOLE OR OXADIAZOLE TO A MAMMAL | BYMASTER FRANKLIN PORTER (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0790995-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1997-08-27 | — | — | EP | disclosed |
| US-5641791-A | USEFUL AS STIMULANTS OF COGNITIVE FUNCTION OF FOREBRAIN AND HIPPOCAMPUS OF MAMMALS AND IN THE TREATMENT OF ALZHIEMER'S DISEASE, SEVERE PAIN AND GLAUCOMA | NOVO NORDISK A.S (DK) | 1997-06-24 | — | — | US | disclosed |
| US-5612351-A | AZABICYCLIC DERIVATIVES OF 1,2,3-OXA(OR THIA)DIAZOLE | NOVO NORDISK A/S (DK) | 1997-03-18 | — | — | US | disclosed |
| US-5578602-A | FOR STIMULATING COGNITIVE FUNCTIONS OF THE BRAIN, TREATING ALZHEIMER*S DISEASE, GLAUCOMA OR PAIN | NOVO NORDISK A/S (DK) | 1996-11-26 | — | — | US | disclosed |
| US-5574043-A | ALZHEIMERS, GLAUCOMA, ANALGESIC | NOVO NORDISK A/S (DK) | 1996-11-12 | — | — | US | disclosed |
| EP-0735869-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-10-09 | — | — | EP | disclosed |
| US-5527813-A | THERAPEUTICALLY ACTIVE AZABICYCLIC COMPOUNDS USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND IN THE TREATMENT OF ALZHEIMER'S DISEASE | NOVO NORDISK A/S (DK) | 1996-06-18 | — | — | US | disclosed |
| EP-0714394-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-06-05 | — | — | EP | disclosed |
| WO-1996014316-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | disclosed |
| EP-0687266-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995017180-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995005379-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994020496-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |